Literature DB >> 11249832

Antimicrobial safety and tolerability: differences and dilemmas.

L A Mandell1, P Ball, G Tillotson.   

Abstract

The adverse drug reactions associated with antimicrobials have become a topic of major importance and concern in the last few years. Antimicrobial toxicity may take many forms, varying from mild, transient phenomena to dramatic, life-threatening events such as seizures or cardiac arrhythmias. We review the toxicity of antimicrobials in general and of the fluoroquinolones in particular and attempt to explain the adverse events by use of structure-adverse event relationships where possible. There are currently 5 main mechanisms that can be invoked to explain antimicrobial toxicity: direct effects, hypersensitivity, changes in microbial flora, drug interactions, and microbial lysis. The adverse drug reactions seen with fluoroquinolones are explained on the basis of these 5 mechanisms. The various organ systems affected by the fluoroquinolones are considered; then individual members of the fluoroquinolone class are reviewed. The unexpected and dramatic problems encountered with temafloxacin and trovafloxacin are discussed as well.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11249832     DOI: 10.1086/319379

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

Review 1.  The dual interaction of antimicrobial peptides on bacteria and cancer cells; mechanism of action and therapeutic strategies of nanostructures.

Authors:  Atefeh Parchebafi; Farzaneh Tamanaee; Hassan Ehteram; Ejaz Ahmad; Hossein Nikzad; Hamed Haddad Kashani
Journal:  Microb Cell Fact       Date:  2022-06-18       Impact factor: 6.352

2.  Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

Authors:  Roberto Leone; Mauro Venegoni; Domenico Motola; Ugo Moretti; Valentina Piazzetta; Alfredo Cocci; Domenico Resi; Federico Mozzo; Giampaolo Velo; Liliana Burzilleri; Nicola Montanaro; Anita Conforti
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs.

Authors:  Guillermo J Ballarino; Kenneth N Olivier; Reginald J Claypool; Steven M Holland; D Rebecca Prevots
Journal:  Respir Med       Date:  2009-05-21       Impact factor: 3.415

Review 4.  Gender analysis of moxifloxacin clinical trials.

Authors:  Elisa Chilet-Rosell; Ma Teresa Ruiz-Cantero; Ma Angeles Pardo
Journal:  J Womens Health (Larchmt)       Date:  2013-11-01       Impact factor: 2.681

5.  In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.

Authors:  Charles E Edmiston; Candace J Krepel; Gary R Seabrook; Lewis R Somberg; Atilla Nakeeb; Robert A Cambria; Jonathan B Towne
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 6.  Peptides with Dual Antimicrobial and Anticancer Activities.

Authors:  Mário R Felício; Osmar N Silva; Sônia Gonçalves; Nuno C Santos; Octávio L Franco
Journal:  Front Chem       Date:  2017-02-21       Impact factor: 5.221

Review 7.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.

Authors:  Sarah C J Jorgensen; Nicholas J Mercuro; Susan L Davis; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2018-03-31

9.  Amoxicillin Modulates ApoA-I Transcription and Secretion, Predominantly via PPARα Transactivation Inhibition.

Authors:  Jehad Z Tayyeb; Herman E Popeijus; Ronald P Mensink; Maurice C J M Konings; Kim H R Mulders; Jogchum Plat
Journal:  Int J Mol Sci       Date:  2019-11-27       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.